Neoadjuvant Chemotherapy with Low-Dose Nivolumab Leading to Complete Pathological Response in Non-small Cell Lung Carcinoma

Lung cancer is the second most commonly diagnosed cancer worldwide and the most common cause of mortality. Locally advanced non-small cell carcinoma is treated with multimodality treatment. Neoadjuvant chemotherapy with or without immunotherapy is known to have a maximal response and improves outcomes in stage III lung cancers. Immunotherapy is not affordable in mid and low-socioeconomic-income countries. Here we report a 69-year-old gentleman treated with neoadjuvant low-dose nivolumab (LDNiv) with chemotherapy followed by surgery and it shows a complete pathological response. LDNiv could be an economical option and could be explored in future prospective studies.